Patient Health Advisory
The Duloxetine Recall: What It Means for You — and the options you may not have been offered
A nationwide recall has pulled hundreds of thousands of bottles of generic Cymbalta from pharmacy shelves over a cancer-linked impurity. If you take duloxetine for pain, here is what actually happened, what to do next, and how we can help you get to the source of the problem — not just quiet the signal.
Jacques Courseault, MD, CAQSM, FAAPMR · The Fascia Institute and Treatment Center®
· Chronic Pain · Fibromyalgia · Hypermobility / EDS · Medication Review
01 · What Was Actually Recalled
A manufacturing problem, not a warning about the medicine itself
In 2025, Breckenridge Pharmaceutical issued a voluntary nationwide recall of duloxetine delayed-release capsules — the generic form of Cymbalta — covering roughly 375,000 bottles in the 30 mg and 60 mg strengths. Laboratory testing had found N-nitroso-duloxetine, a “nitrosamine” impurity, at levels above the FDA’s recommended limit. The affected capsules were manufactured by Towa Pharmaceuticals Europe and distributed in the U.S. under more than one label.
The FDA classified it as a Class II recall — meaning use of the product could cause temporary or medically reversible effects, with serious harm considered remote. Importantly, this was not a one-time event: duloxetine has been recalled repeatedly since 2024 over the same impurity, and no adverse events have been linked to the recalled lots.
In plain terms
Nitrosamines are trace impurities that can form during a drug’s manufacturing or storage. They have turned up in many common medications in recent years — blood-pressure pills, heartburn drugs, and now some generic antidepressants. They matter because, in large amounts over a long time, they are considered probable cancer-causing compounds.
02 · How Worried Should You Be?
Serious enough to review — not a reason to panic
The risk from nitrosamines comes from exposure above acceptable limits over long periods — not from a single dose or a few weeks of use. The FDA’s own framing is reassuring: a person taking a drug that contains nitrosamines at or below the acceptable daily intake, every day for 70 years, is not expected to have an increased risk of cancer.
So this is best understood as a manufacturing-quality problem rather than a medical emergency. But it is also a perfectly good moment to step back and ask a bigger question: is duloxetine still the right tool for you — or has it simply become the tool you were handed?
03 · What To Do Right Now
Four steps, in order
1. Do not stop duloxetine suddenly.
Stopping abruptly can trigger discontinuation syndrome — “brain zaps,” dizziness, nausea, headaches, sleep disruption, mood swings, and flu-like symptoms. Some studies suggest close to half of people who stop feel some of this. Any change should be a gradual, physician-guided taper — typically over several weeks or longer — never cold turkey.
2. Check your bottle.
Ask your pharmacist whether your specific lot number and manufacturer are part of the recall. The recall covers certain lots — not every duloxetine prescription in the country.
3. Know that you can still get duloxetine.
The drug is not banned. Pharmacies can dispense unaffected product from other manufacturers, so a recall does not have to mean an interruption in your treatment.
4. Talk to a physician about the bigger picture.
A recall is a natural prompt to ask whether this is still your best option — or whether there is something that treats the cause of your pain rather than masking it.
04 · Why So Many of Our Patients Are On It
Duloxetine turns down the volume — it doesn’t fix the wiring
Duloxetine is an SNRI. It is approved for depression and anxiety, but also for fibromyalgia, diabetic nerve pain, and chronic musculoskeletal pain — and that last group is why we see it so often at The Fascia Institute. Many people living with fascial pain, fibromyalgia, and hypermobility- or EDS-related pain are placed on duloxetine to dampen an over-sensitized pain system.
It can genuinely help. But it manages a symptom — it does not answer why the tissue hurts. When pain is coming from restricted, adhered, or injured fascia, quieting the nervous system only goes so far. Find and treat the mechanical source, and many patients need far less medication to feel well.
If you take duloxetine primarily for depression or anxiety, that is a conversation for you and your mental-health provider — please keep working with them. The options below are about the pain side of the picture.
05 · Medication Options Worth Discussing
If duloxetine isn’t right for you, it isn’t the only medicine
These are options your prescriber may consider for the same pain conditions. None is a personal recommendation — every one has its own trade-offs — but they are worth knowing about so you can have an informed conversation:
· Unaffected duloxetine from a different, non-recalled manufacturer — often the simplest fix.
· Other SNRIs such as venlafaxine or desvenlafaxine, which work through a similar mechanism.
· Pregabalin (Lyrica) or milnacipran (Savella) — both FDA-approved specifically for fibromyalgia.
· Gabapentin or low-dose tricyclics (amitriptyline, nortriptyline) for nerve-related pain.
Our physicians are happy to review your full regimen and coordinate with your prescriber to find a better-tolerated fit — while we work on the underlying driver of the pain.
06 · Beyond Medication — Treating the Root Cause
What we actually do at The Fascia Institute
Our goal is to locate and treat the source of your pain — most often in the fascia — so that, over time, you may be able to rely less on medication. A typical path starts with imaging and works toward targeted, regenerative, and metabolic care.
Start Here · Diagnostic
Fascial Mapping
High-resolution ultrasound to pinpoint the exact fascial planes, adhesions, and restrictions generating your pain — so treatment is aimed, not guessed.
Signature Procedure
Hydrofascia Release™
Dr. Courseault’s ultrasound-guided hydrodissection — the technique he first published on — that releases restricted, pain-generating fascia at depths that hands-on therapy can’t reach.
Regenerative
ProloBoost™ Dual PRP
Concentrated platelet-rich plasma injections that support the body’s own repair of injured and pain-prone connective tissue.
Metabolic
FLIP · GLP-1 Program
Physician-run, connective-tissue-aware GLP-1 care — slow, monitored, and built for patients with hypermobility, MCAS, or lipedema whose pain has a metabolic layer.
Two more tools often round out the plan: our FIT GPS genomic screen looks for root-cause metabolic drivers — including folate and MTHFR variants tied to both pain and mood — and our Hypermobility & EDS Clinic is built for the connective-tissue patients who most often end up on medications like duloxetine in the first place.
Common Questions
References & Further Reading
1. Pharmaceutical Technology — FDA Duloxetine Recall Highlights Generic Manufacturing Quality Gaps.
2. Pharmacy Times — FDA Recalls 233,000 Bottles of Duloxetine Over Risk of Cancerous Chemical.
3. U.S. FDA — Information about Nitrosamine Impurities in Medications (acceptable-intake and cancer-risk framing).
4. NCBI / PMC — Pain Management in Fibromyalgia: Evaluating the Roles of Pregabalin, Duloxetine, and Milnacipran.
5. Mayo Clinic — Antidepressants: Another tool against chronic pain.
6. Courseault J, et al. — Ultrasound-guided fascial hydrodissection for chronic musculoskeletal pain, Current Sports Medicine Reports (2019).
This article is for general education and is not medical advice. It does not create a physician–patient relationship. Do not start, stop, or change any medication without guidance from your prescribing physician. If you take duloxetine for depression or anxiety, continue working with your mental-health provider. The Fascia Institute and Treatment Center® · 2520 Harvard Ave, Ste 2B, Metairie, LA 70001 · (504) 704-1254.